Search

Additional file 1. Table S1. Reported symptoms of all participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n=492); no symptom duration outliers excluded. Table S2. Reported symptoms of all participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n=492); mild and extreme symptom duration outliers excluded. Table S3. Sensitivity of the rapid antibody test# by symptom duration and outlier exclusion criteria. Fig. S1. Plots of antibody test sensitivity against the number of weeks since onset of symptoms among those who reported at least one symptom before testing, using the RT-PCR test as the reference, stratified by the types of outliers excluded in the analysis: extreme outliers, which were defined as persons whose time since symptom onset was longer than the third quartile plus 3 times the interquartile range (IQR, defined as the difference between the first and third quartile of the reported times since onset for a given symptom); mild outliers were those beyond the third quartile plus 1.5 times the IQR); or no outliers excluded. The circles show the crude estimated sensitivity and the error bars show the Wilson’s score 95% confidence intervals. The plotted lines are the fitted segmented linear regressions for the rapid antibody tests. Table S4. Segmented regression analyses of antibody test sensitivity by weeks since symptom onset, by symptom duration outlier exclusion criteria. Table S5. Overall antibody test sensitivity* per week since symptom onset for common symptoms. Table S6.Segmented regression analyses of antibody test sensitivity versus weeks since symptom onset, by symptom.

BACKGROUND Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically changed. After long years of stagnation, new compounds entered the market (bedaquiline, delamanid and pretomanid) and phase III clinical trials have shown promising results towards shortening duration of treatment for both drug-susceptible (Study 31/A5349, TRUNCATE-TB, SHINE) and drug-resistant tuberculosis (STREAM, NiX-TB, ZeNix, TB-PRACTECAL). Dose optimization of rifamycins and repurposed drugs have also brought hopes of further development of safe and effective regimens. Consequently, international and World Health Organization clinical guidelines have been updated multiple times in the last years to keep pace with these advances. OBJECTIVES This narrative review aims to summarize the state-of-the-art on treatment of drug-susceptible and drug-resistant tuberculosis, as well as recent trials results and an overview of ongoing clinical trials. SOURCES A non-systematic literature review was conducted in PubMed and MEDLINE, focusing on the treatment of tuberculosis. Ongoing clinical trials were listed according to the authors' knowledge, and completed consulting clinicaltrials.gov and other publicly available websites (www.resisttb.org/clinical-trials-progress-report, www.newtbdrugs.org/pipeline/trials). CONTENT This review summarizes the recent, major changes in the landscape for drug-susceptible and drug-resistant treatment, with a specific focus on their potential impact on patient outcomes and programmatic TB management. Moreover, insights in host-directed therapies, and advances in pharmacokinetic and pharmacogenomics are discussed. A thorough outline of ongoing therapeutic clinical trials is presented, highlighting different approaches and goals in current TB clinical research. IMPLICATIONS Future research should be directed to individualize regimens and protect these recent breakthroughs by preventing and identifying the selection of drug resistance and providing widespread, affordable, patient-centered access to new treatment options for all people affected by tuberculosis.

We surveyed awardees of the Minority HIV Investigator Mentoring Program (MHIMP) of the AIDS Clinical Trials Group. Most reported clinical specialization in infectious diseases or HIV medicine (86%), and all but 1 (95%) are engaged in medical/health sciences research. The MHIMP helped retain early-career minority investigators in HIV/AIDS-related research.